View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/FDA RIN: 0910-AG04 Publication ID: Fall 2007 
Title: ●Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals 
Abstract: The Food and Drug Administration (FDA) is amending certain sections of 21 CFR parts 210 and 211 as the first phase of an incremental approach to modifying the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in 21 CFR parts 210 and 211. We are amending the regulations to modernize or clarify some of the CGMP requirements, as well as harmonize some of the CGMP requirements with those of other foreign regulators and other FDA regulations. These amendments are also consistent with current industry practice. We are taking this action as part of our continuing effort to revise outdated regulations without diminishing public health protection. 
Agency: Department of Health and Human Services(HHS)  Priority: Routine and Frequent 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 210 to 211   
Legal Authority: 21 USC 321    21 USC 351 to 352    21 USC 355    21 USC 360b    21 USC 371    21 USC 374    42 USC 216    42 USC 262    42 USC 263a to 264   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM-Companion to Direct Final Rule  11/00/2007    
Direct Final Rule  11/00/2007    
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Jessica Tave
Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research, 1401 Rockville Pike, Suite 200N, HFM-600,
Rockville, MD 20852
Phone:301 827-6190